From 2010 Annual Report: FUSILEV SALES MAY NOT BE SUSTAINABLE
Product sales in 2010 were $61M
Zevalin $29M up from $16M in 2009
Fusilev $32M up from $13M in 2009
Our revenue from Fusilev sales may not be sustainable and our customer concentration is significant
Most of the Fusilev revenue the Company recorded in 2010 resulted from the leucovorin drug shortage, the depth of which we cannot predict. Even with approval for colorectal cancer a possibility in 2011, there is not surety that Fusilev sales will be sustainable. Our customer concentration of Fusilev is high. Sales to Customer A for the years ended December 31, 2010, 2009 and 2008 were 45.7%, 27.1%, and 35.7% respectively, of our total consolidated gross product sales. If our relationship with our top distributors is impaired our sales of Fusilev would be negatively impacted.
If we are unable to expand the approved usage of Fusilev, the product’s operating results may be harmed, which could adversely affect our financial and operating results.
We have filed a supplemental new drug application for Fusilev for use in combination with 5#$%$-containing regimens in the treatment of colorectal cancer. The greatest potential use of this product is in this indication. If we are not able to obtain approval for this indication, we may not recognize the full anticipated value of our investment in the product and our financial and operating results could be adversely affected.
redoak, what about the 8 quarterly conference calls and atleast 8 investor conf presentations in 2011 and 2012, where he continually made those materially misleading statements on Fusilev. You think putting something in 10k and then saying opposite thing in 16 conf calls over 2 years and then selling stock $8.8m, will absolve this guy from saying any #$%$ and selling stock?
So much for all these law suits and people claiming Raj and Spectrum did not warn anyone. How transparent can you get. I supose the claim will be he did not say this ever second of every day. I remember this statement. Thanks redoak.
Our revenue from FUSILEV sales may not be sustainable and our customer concentration is significant
There is no assurance that FUSILEV sales will be sustainable at its current levels. Our customer concentration of FUSILEV is high. Sales to Customer A for the years ended December 31, 2011, 2010 and 2009 were 57.0%, 45.7% and 27.1%, respectively, of our total consolidated gross product sales. Sales to Customer B for the year ended December 31, 2011 were 19.1% of our total consolidated gross product sales. If our relationship with our top distributors is impaired our sales of FUSILEV would be negatively impacted.
the point is that sppi mgmt knew all along that fusilev sales were not sustainable and let everyone know. no secrets. sppi mgmt took full advantage of the shortage to move their business plan ahead of schedule. If anyone invested in sppi solely on the basis of fusilev sales than you should have walked away in july. there is so much more to sppi than just fusilev.